Alvotech (ALVO) Q1 2026 Earnings Transcript

Alvotech reported Q1 revenue of $106 million, down 20% year over year due to milestone timing and a manufacturing slowdown from facility improvements, but adjusted EBITDA rose to $24 million with a 23% margin versus 15% a year ago. Management kept 2026 guidance intact at $650 million-$700 million in revenue and $180 million-$220 million in adjusted EBITDA, highlighted a $64 million cash balance, and said production should normalize this quarter. The company also said FDA inspection work is ongoing, BLA resubmissions for AVT03, AVT05 and AVT06 are targeted for Q2, and a new Fujifilm manufacturing partnership should add U.S. supply capacity beginning in 2H 2027.

Analysis

The setup is less about this quarter’s revenue miss and more about a temporary suppression of earnings power ahead of multiple binary regulatory catalysts. The market is likely underappreciating the operating leverage embedded in a normalized manufacturing run-rate: once throughput resets, incremental revenue should convert unusually well because the company is already carrying the fixed cost base and the next leg of growth is largely launch-driven rather than discovery-driven.

The bigger second-order effect is that the Fujifilm deal is not just supply insurance; it is a de-risking mechanism for U.S. commercialization and future launch sequencing. That matters because the equity has been trading as if Reykjavik is a single-point-of-failure asset, while management is effectively buying optionality on future volume growth and reducing the probability that a regulator-induced interruption derails the 2027 expansion story.

The contrarian risk is that investors may be too anchored to the “regulatory cleanup” narrative and not enough to cash burn. Positive EBITDA is not the same as self-funding when working capital, interest expense, and intangible investment remain heavy; that creates a financing overhang if the Q2 resubmission or inspection cleanly closes but product normalization lags into 2H. The fastest path to downside is not a bad headline, but a delay in revenue recognition combined with another quarter where cash conversion fails to track reported margins.

Relative value is clearer in the partner set than in ALVOW itself. TEVA gets the cleaner near-term benefit from continued biosimilar uptake without carrying the same concentration of regulatory/manufacturing execution risk, while ALVOW is the higher-beta call option on 2027 capacity and pipeline milestones. Consensus appears to be treating the current softness as cyclical; the more interesting possibility is that earnings inflect sharply if the company exits this remediation period with no further inspection noise and the first wave of pending biosimilars reopens the growth algorithm.

Key Decisions for Investors

• Go long ALVOW only on confirmation that the current inspection closes without material findings; use a 3-6 month horizon and size as a catalyst trade, not a core position. Upside is meaningful if Q2 resubmission lands on time and Q4 becomes the inflection quarter, but downside is material if the process slips again.
• Pair trade: long TEVA / short ALVOW into the next 1-2 quarters. TEVA captures biosimilar uptake with less single-site regulatory risk, while ALVOW still has working-capital and inspection overhangs; this is the cleaner way to express a constructive view on biosimilar adoption.
• Consider buying ALVOW out-of-the-money calls into the Q2 resubmission window only if implied vol is not already inflated. The trade benefits from a discrete rerating on regulatory closure, with defined downside versus common stock.
• If already long ALVOW, hedge with a partial short against a healthcare basket or reduce into strength after any inspection close headline; the stock can gap on news, but the business still needs two clean quarters to prove cash conversion.
• Avoid adding on the thesis that EBITDA margin alone fixes the story; wait for evidence that operating cash flow improves alongside revenue normalization, otherwise the equity remains vulnerable to another financing discussion.